LIVIVO - Search results -

Search results

Result 1 - 10 of total 12

Search options

Article: Perforated jeyunal diverticulitis: a rare cause of acute abdomen.

Santos Rancaño, Rocío / Delgado Morales, Mariela / Hernández García, Miguel / Cerdán Santacruz, Carlos / Buendía Pérez, Emilio / Alonso Guillén, Ramón

Gastroenterologia y hepatologia

2020 Volume 44, Issue 8, Page(s) 563–564

Title translation	Diverticulitis yeyunal perforada: una causa rara de abdomen agudo.
MeSH term(s)	Abdomen, Acute/etiology ; Aged ; Diverticulitis/complications ; Diverticulitis/surgery ; Female ; Humans ; Intestinal Perforation/complications ; Intestinal Perforation/surgery ; Jejunal Diseases/complications ; Jejunal Diseases/surgery ; Rare Diseases/complications ; Rare Diseases/surgery
Language	Spanish
Publishing date	2020-10-20
Publishing country	Spain
Document type	Case Reports
ZDB-ID	632502-6
ISSN	0210-5705
ISSN	0210-5705
DOI	10.1016/j.gastrohep.2020.07.024
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2044: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Bone marrow trephine biopsy in Hodgkin's lymphoma. Comparison with PET-CT scan in 65 patients.

Lakhwani, Sunil / Cabello-García, Dolores / Allende-Riera, Ana / Cárdenas-Negro, Carlos / Raya, José María / Hernández-Garcia, Miguel T

Medicina clinica

2017 Volume 150, Issue 3, Page(s) 104–106

Abstract: Background and objectives: To compare bone marrow biopsy (BMB) and PET/CT in detecting bone marrow involvement in Hodgkin's lymphoma MATERIAL AND METHODS: Retrospective analysis of 65 patients with both tests in the initial staging or in relapse with ... ...

Title translation	Biopsia de médula ósea en el linfoma de Hodgkin. Comparación con la PET-TC en 65 pacientes.
Abstract	Background and objectives: To compare bone marrow biopsy (BMB) and PET/CT in detecting bone marrow involvement in Hodgkin's lymphoma MATERIAL AND METHODS: Retrospective analysis of 65 patients with both tests in the initial staging or in relapse with special attention to the PET/CT uptake pattern. Results: In 3 patients (4.6%), the BMB showed bone marrow involvement with the PET/CT being positive in them all: 2 with diffuse+multifocal pattern and one diffuse only. In 11 additional patients (total 14/65, 21%), bone marrow involvement was diagnosed by PET/CT because bone marrow uptake was above hepatic one. The pattern was focal only in 2 cases, multifocal in 5, diffuse in 3 and diffuse+multifocal in one. In these last 4 cases the BMB showed an unspecific myelopathy. Conclusions: PET/CT detects all cases with BMB affected and many that escape to biopsy, however when the uptake pattern is diffuse it could be by involvement or reactive hyperplasia and in those cases the BMB should be done.
MeSH term(s)	Adolescent ; Adult ; Aged ; Biopsy ; Bone Marrow/pathology ; Female ; Hodgkin Disease/diagnostic imaging ; Hodgkin Disease/pathology ; Humans ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Retrospective Studies ; Young Adult
Language	Spanish
Publishing date	2017-08-31
Publishing country	Spain
Document type	Comparative Study ; Journal Article
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1016/j.medcli.2017.06.060
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.

Manzanedo, Israel / Pereira, Fernando / Pérez-Viejo, Estíbalitz / Serrano, Ángel / Hernández-García, Miguel / Martínez-Torres, Beatriz / Rihuete-Caro, Cristina / Calzas, Julia / Cueto, Margarita

Minerva ginecologica

2016 Volume 69, Issue 2, Page(s) 119–127

Abstract: Background: Peritoneal dissemination is the most common route of spread of epithelial ovarian cancer (EOC). Cytoreductive surgery (CRS) followed by platinum-based systemic chemotherapy is the current standard treatment in advanced stages, with ... ...

Abstract	Background: Peritoneal dissemination is the most common route of spread of epithelial ovarian cancer (EOC). Cytoreductive surgery (CRS) followed by platinum-based systemic chemotherapy is the current standard treatment in advanced stages, with suboptimal results. The aim of this study is to analyze the outcome of advanced EOC treated with CRS plus hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) combined with systemic chemotherapy. Methods: We analyze a cohort of women treated with CRS plus HIPEC for peritoneal carcinomatosis secondary to EOC from May 2007 to December 2014. We included both patients with peritoneal disease at first diagnosis of EOC and peritoneal recurrences after initial treatment. Results: We performed 61 CRS with HIPEC procedures, 31 cases as primary treatment (4 as upfront therapy and 27 after neoadjuvant chemotherapy) and 30 as secondary treatment (recurrences). Median Peritoneal Carcinomatosis Index (PCI) was 9; the cytoreduction was optimal in 92% of the procedures. Severe morbidity (Grade III-IV of Clavien-Dindo classification) was 29.5%, without mortality. Median follow-up was 23 months and median disease-free survival (DFS) was 14 months (14 in primary surgery group and 17 in recurrence group, P=0.51). Median overall survival (OS) was 57 months; in primary surgery group, OS was 96.8% at 1 year, and 55% at 5 years, and median OS was not reached; OS in recurrence group was 89.3% at 1 year and 47.1% at 5 years, and median OS was 57 months. Conclusions: CRS with HIPEC is a treatment option for EOC with good results in terms of morbidity and survival, in experienced centers.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Carcinoma, Ovarian Epithelial ; Cohort Studies ; Combined Modality Therapy ; Cytoreduction Surgical Procedures/methods ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Hyperthermia, Induced/methods ; Injections, Intraperitoneal ; Middle Aged ; Neoadjuvant Therapy/methods ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial/pathology ; Neoplasms, Glandular and Epithelial/therapy ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Peritoneal Neoplasms/pathology ; Peritoneal Neoplasms/secondary ; Peritoneal Neoplasms/therapy ; Prospective Studies ; Survival Rate
Language	English
Publishing date	2016-07-14
Publishing country	Italy
Document type	Journal Article
ZDB-ID	80159-8
ISSN	1827-1650 ; 0026-4784 ; 0325-8793
ISSN (online)	1827-1650
ISSN	0026-4784 ; 0325-8793
DOI	10.23736/S0026-4784.16.03959-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Um I Zs.245: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Leucemia aguda de células precursoras mieloides/natural killer de presentación simultánea con leucemia linfática crónica.

Morabito, Lucio / Raya Sánchez, José María / Hernández García, Miguel T / Hernández Nieto, Luis

Medicina clinica

2008 Volume 131, Issue 9, Page(s) 356

Title translation	Chronic lymphocytic leukemia concurrent with myeloid/natural killer cell precursor acute leukemia diagnosis.
MeSH term(s)	Aged ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Neoplasms, Multiple Primary/diagnosis ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
Language	Spanish
Publishing date	2008-09-20
Publishing country	Spain
Document type	Case Reports ; Letter
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.

Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández-Garcia, Miguel Teodoro / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabela / Mercadal, Santiago / Galeo, Andrea / Jiménez, Javier López / Moraleda, José M / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /

Palomera, Luis / Jarque, Isidro / Rodriguez, Antonia / Lorza, Leyre / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / José Lahuerta, Juan

Hematology/oncology and stem cell therapy

2019 Volume 12, Issue 4, Page(s) 194–203

Abstract: Objective/background: Patients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in ... ...

Abstract	Objective/background: Patients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in patients from the Grupo Español de Linfomas y Trasplantes de Médula Ósea (GELTAMO) registry treated with rituximab prior to ASCT and with ETF after first-line immunochemotherapy, leading to 81% 5-year OS since ASCT. We explored whether ASCT is also an effective option in the pre-rituximab era-that is, in patients treated in induction and rescued only with chemotherapy. Methods: ETF was defined as relapse/progression within 2 years of starting first-line therapy. We identified two groups: the ETF cohort (n = 87) and the non-ETF cohort (n = 47 patients receiving ASCT but not experiencing ETF following first-line therapy). Results: There was a significant difference in 5-year progression-free survival between the ETF and non-ETF cohorts (43% vs. 57%, respectively; p = .048). Nevertheless, in patients with ETF with an interval from first relapse after primary treatment to ASCT of <1 year, no differences were observed in 5-year progression-free survival (48% vs. 66%, respectively; p = .44) or in 5-year OS (69% vs. 77%, p = .4). Patients in the ETF cohort transplanted in complete remission showed a plateau in the OS curves, at 56%, beyond 13.7 years of follow-up. Conclusion: ASCT may be a curative option for ETF in patients who respond to rescue chemotherapy, without the need for immunotherapy or other therapies, and should be considered as an early consolidation, especially in patients with difficult access to rituximab.
MeSH term(s)	Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Registries ; Rituximab/administration & dosage ; Stem Cell Transplantation ; Survival Rate
Chemical Substances	Rituximab (4F4X42SYQ6)
Language	English
Publishing date	2019-07-09
Publishing country	England
Document type	Journal Article
ZDB-ID	2651893-4
ISSN	1658-3876
ISSN	1658-3876
DOI	10.1016/j.hemonc.2019.06.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6950: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment.

Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández-Garcia, Miguel Teodoro / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabela / Mercadal, Santiago / Galeo, Andrea / Jiménez, Javier López / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /

Palomera, Luis / Jarque, Isidro / Martínez-Sánchez, Pilar / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

Hematological oncology

2018 Volume 36, Issue 5, Page(s) 765–772

MeSH term(s)	Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Registries ; Rituximab ; Spain/epidemiology ; Survival Rate
Chemical Substances	Rituximab (4F4X42SYQ6)
Language	English
Publishing date	2018-09-12
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Multicenter Study
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.2553
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.

Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Hernández-Garcia, Miguel Teodoro / Novelli, Silvana / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabella / Mercadal, Santiago / Galeo, Andrea / Jiménez, Javier López / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura / Palomera, Luis /

Jarque, Isidro / Martínez-Sánchez, Pilar / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

Bone marrow transplantation

2018 Volume 53, Issue 6, Page(s) 780–783

MeSH term(s)	Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Lymphoma, Follicular/complications ; Lymphoma, Follicular/pathology ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Neoplasms, Second Primary ; Registries ; Retrospective Studies ; Rituximab ; Survival Analysis ; Transplantation, Autologous/adverse effects ; Transplantation, Autologous/methods
Chemical Substances	Rituximab (4F4X42SYQ6)
Language	English
Publishing date	2018-01-23
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-018-0096-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.

Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández-Garcia, Miguel Teodoro / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabella / Mercadal, Santiago / Galeo, Andrea / López Jiménez, Javier / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /

Palomera, Luis / Jarque, Isidro / Martínez-Sánchez, Pilar / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2017 Volume 23, Issue 10, Page(s) 1631–1640

Abstract: High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a ... ...

Abstract	High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a rituximab-free chemotherapy regimen. A total of 655 patients with FL were reported to the Spanish GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) registry and underwent first ASCT between 1989 and 2007. A total of 203 patients underwent ASCT in first complete response (CR1), 174 in second complete response (CR2), 28 in third complete response (CR3), 140 in first partial response (PR1), 81 in subsequent PR, and 29 with resistant/refractory disease; 184 patients received rituximab before ASCT. With a median follow-up of 12 years from ASCT, median progression-free survival (PFS) and overall survival (OS) were 9.7 and 21.3 years, respectively. Actuarial 12-year PFS and OS were 63% (95% confidence interval [CI], 58%-68%) and 73% (95% CI, 68%-78%), respectively, for patients in CR (with a plateau in the curve beyond 15.9 years), 25% (95% CI, 19%-28%) and 49% (95% CI 42%-56%), respectively, for patients in PR, and 23% (95% CI, 8%-48%) and 28% (95% CI, 9%-45%), respectively, for patients with resistant/refractory disease (P < .001). In patients who received rituximab before ASCT, the estimated 9-year PFS and OS from ASCT were 59.5% (95% CI, 51%-67%) and 75% (95% CI, 68%-83%), respectively. Interestingly, for patients who underwent transplantation in CR ≥2 or PR ≥2 who had received rituximab before ASCT (n = 90), 9-year PFS and OS were 61% (95% CI, 51%-73%) and 75% (95% CI, 65%-80%), respectively, with no relapses occurring beyond 5.1 years after ASCT. The cumulative incidence of second malignancies in the global series was 6.7% at 5 years and 12.8% at 10 years. This analysis strongly suggests that ASCT is a potentially curative option for eligible patients with FL. In the setting of relapse, it is of especial interest in pretransplantation rituximab-sensitive patients with FL.
Language	English
Publishing date	2017-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2017.05.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Rosiñol, Laura / García-Sanz, Ramón / Lahuerta, Juan José / Hernández-García, Miguel / Granell, Miquel / de la Rubia, Javier / Oriol, Albert / Hernández-Ruiz, Belén / Rayón, Consuelo / Navarro, Isabel / García-Ruiz, Juan Carlos / Besalduch, Joan / Gardella, Santiago / López Jiménez, Javier / Díaz-Mediavilla, Joaquín / Alegre, Adrián / San Miguel, Jesús / Bladé, Joan

Haematologica

2011 Volume 97, Issue 4, Page(s) 616–621

Abstract: Background: Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the ... ...

Abstract	Background: Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease. Design and methods: In the Spanish Myeloma Group 2000 trial, 80 patients with primary refractory myeloma (49 with stable disease and 31 with progressive disease), i.e. who were refractory to initial chemotherapy, were scheduled for tandem transplants (double autologous transplant or a single autologous transplant followed by an allogeneic transplant). Patients with primary refractory disease included those who never achieved a minimal response (≥ 25% M-protein decrease) or better. Responses were assessed using the European Bone Marrow Transplant criteria. Results: There were no significant differences in the rates of partial response or better between patients with stable or progressive disease. However, 38% of the patients with stable disease at the time of transplantation remained in a stable condition or achieved a minimal response after transplantation versus 7% in the group with progressive disease (P=0.0017) and the rate of early progression after transplantation was significantly higher among the group with progressive disease at the time of transplantation (22% versus 2%; P=0.0043). After a median follow-up of 6.6 years, the median survival after first transplant of the whole series was 2.3 years. Progression-free and overall survival from the first transplant were shorter in patients with progressive disease (0.6 versus 2.3 years, P=0.00004 and 1.1 versus 6 years, P=0.00002, respectively). Conclusions: Our results show that patients with progressive refractory myeloma do not benefit from autologous transplantation, while patients with stable disease have an outcome comparable to those with chemosensitive disease.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease Progression ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Survival Analysis ; Transplantation, Autologous ; Treatment Outcome
Language	English
Publishing date	2011-11-04
Publishing country	Italy
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2011.051441
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

Haematologica

2010 Volume 95, Issue 11, Page(s) 1913–1920

Abstract: Background: The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) and melphalan 200 mg/m(2) as conditioning regimens for autologous stem cell transplantation in newly diagnosed ... ...

Abstract	Background: The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) and melphalan 200 mg/m(2) as conditioning regimens for autologous stem cell transplantation in newly diagnosed patients with multiple myeloma in the GEM2000 study. Design and methods: The first 225 patients received oral busulfan 12 mg/kg plus melphalan 140 mg/m(2); because of a high frequency of veno-occlusive disease, the protocol was amended and a further 542 patients received melphalan 200 mg/m(2). Results: Engraftment and hospitalization times were similar in both groups. Oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) resulted in higher transplant-related mortality (8.4% versus 3.5%; P=0.002) due to the increased frequency of veno-occlusive disease in this group. Response rates were similar in both arms. With respective median follow-ups of 72 and 47 months, the median progression-free survival was significantly longer with busulfan plus melphalan (41 versus 31 months; P=0.009), although survival was similar to that in the melphalan 200 mg/m(2) group. However, access to novel agents as salvage therapy after relapse/progression was significantly lower for patients receiving busulfan plus melphalan (43%) than for those receiving melphalan 200 mg/m(2) (58%; P=0.01). Conclusions: Conditioning with oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) was associated with longer progression-free survival but equivalent survival to that achieved with melphalan 200 mg/m(2) but this should be counterbalanced against the higher frequency of veno-occlusive disease-related deaths. This latter fact together with the limited access to novel salvage therapies in patients conditioned with oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) may explain the absence of a survival difference. Oral busulfan was used in the present study; use of the intravenous formulation may reduce toxicity and result in greater efficacy, and warrants further investigation in myeloma patients. (Clinicaltrials.gov identifier: NCT00560053).
MeSH term(s)	Aged ; Aged, 80 and over ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Female ; Follow-Up Studies ; Humans ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Myeloablative Agonists/administration & dosage ; Myeloablative Agonists/adverse effects ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation Conditioning ; Transplantation, Autologous
Chemical Substances	Myeloablative Agonists ; Busulfan (G1LN9045DK) ; Melphalan (Q41OR9510P)
Language	English
Publishing date	2010-07-27
Publishing country	Italy
Document type	Clinical Trial ; Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2010.028027
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito